| Protein expression and functional relevance of efflux and uptake drug transporters at the blood–brain barrier of human brain and glioblastoma X Bao, J Wu, Y Xie, S Kim, S Michelhaugh, J Jiang, S Mittal, N Sanai, J Li Clinical Pharmacology & Therapeutics 107 (5), 1116-1127, 2020 | 55 | 2020 |
| Post-transcriptional modifications modulate rRNA structure and ligand interactions J Jiang, H Seo, CS Chow Accounts of chemical research 49 (5), 893-901, 2016 | 37 | 2016 |
| Structure modulation of helix 69 from Escherichia coli 23S ribosomal RNA by pseudouridylations J Jiang, R Aduri, CS Chow, J SantaLucia Jr Nucleic acids research 42 (6), 3971-3981, 2014 | 30 | 2014 |
| Physiologically based pharmacokinetic modeling of central nervous system pharmacokinetics of CDK4/6 inhibitors to guide selection of drug and dosing regimen for brain cancer … J Li, J Jiang, J Wu, X Bao, N Sanai Clinical Pharmacology & Therapeutics 109 (2), 494-506, 2021 | 22 | 2021 |
| The RNA folding problems: different levels of sRNA structure prediction F Sijenyi, P Saro, Z Ouyang, K Damm-Ganamet, M Wood, J Jiang, ... RNA 3D structure analysis and prediction, 91-117, 2012 | 22 | 2012 |
| Comparison of solution conformations and stabilities of modified helix 69 rRNA analogs from bacteria and human M Sumita, J Jiang, J SantaLucia Jr, CS Chow Biopolymers 97 (2), 94-106, 2012 | 22 | 2012 |
| Quantitative protein expression of blood‐brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer X Bao, J Wu, J Jiang, AC Tien, N Sanai, J Li Clinical and Translational Science 14 (4), 1265-1271, 2021 | 10 | 2021 |
| Helix 69: a multitasking RNA motif as a novel drug target J Jiang, Y Sakakibara, CS Chow Israel Journal of Chemistry 53 (6‐7), 379-390, 2013 | 10 | 2013 |
| Inhibition of cysteine protease papain by metal ions and polysulfide complexes, especially mercuric ion Mercury polysulfide complexes might be potential bioactive species in … J Jiang, X Yang, K Wang Journal of Chinese Pharmaceutical Sciences 16 (1), 1, 2007 | 10 | 2007 |
| Mechanistic modeling of central nervous system pharmacokinetics and target engagement of HER2 Tyrosine Kinase inhibitors to inform treatment of breast cancer brain metastases J Li, J Jiang, X Bao, V Kumar, SC Alley, S Peterson, AJ Lee Clinical Cancer Research 28 (15), 3329-3341, 2022 | 9 | 2022 |
| Modulation of conformational changes in helix 69 mutants by pseudouridine modifications Jun Jiang, Daya Nidhi Kharel, Christine S. Chow Biophysical Chemistry, 2015 | 8 | 2015 |
| Amino acid-linked platinum (II) compounds: non-canonical nucleoside preferences and influence on glycosidic bond stabilities B Kimutai, CC He, A Roberts, ML Jones, X Bao, J Jiang, Z Yang, ... JBIC Journal of Biological Inorganic Chemistry 24, 985-997, 2019 | 6 | 2019 |
| Evaluation and correction of injection order effects in LC-MS/MS based targeted metabolomics Y Yue, X Bao, J Jiang, J Li Journal of Chromatography B 1212, 123513, 2022 | 5 | 2022 |
| DDRE-23. PRECLINICAL EVALUATION OF BRAIN PENETRATION PROPERTIES OF NEW FIRST-IN-CLASS LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITOR, SP-2577 J Jiang, B Hopkins, G Hook, EL Melendez, A Tovmasyan, S Mehta, J Li, ... Neuro-Oncology 23 (Suppl 6), vi79, 2021 | 2 | 2021 |
| Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors J Jiang, X Bao, Y Yue, D Schiff, R Bindra, J Li Biomedical Chromatography 36 (12), e5478, 2022 | 1 | 2022 |
| 287MO A phase 0 ‘trigger’trial of pamiparib in newly diagnosed and recurrent glioblastoma patients N Sanai, SN Mehta, YW Chang, J Jiang, J Molloy, C Pennington-Krygier, ... Annals of Oncology 33, S670, 2022 | 1 | 2022 |
| Abstract CT125: A phase 0/2 ‘trigger’trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma N Sanai, YW Chang, J Jiang, J Molloy, C Pennington-Krygier, J Harmon, ... Cancer Research 84 (7_Supplement), CT125-CT125, 2024 | | 2024 |
| Differential metabolic response of triple-negative and estrogen receptor-positive breast cancer cells to abemaciclib, a CDK4/6 inhibitor J Jiang, X Bao, Y Jiang, Y Yue, M Huettemann, J Li Cancer Research 84 (6_Supplement), 4424-4424, 2024 | | 2024 |
| SINGLE CELL TRANSCRIPTOMICS, PHARMACOKINETICS, AND PHARMACODYNAMICS OF COMBINED CDK4/6 AND MTOR INHIBITION IN A PHASE 0 TRIAL OF RECURRENT HIGH-GRADE GLIOMA K Johnson, AC Tien, J Jiang, J McNamara, YW Chang, C Montgomery, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
| A Combined Phase 0/2" Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma WR Kennedy, YW Chang, J Jiang, J Molloy, C Pennington-Krygier, ... International Journal of Radiation Oncology, Biology, Physics 117 (2), e115, 2023 | | 2023 |
Mary T. RodgersProfessor of Analytical and Physical Chemistry, Wayne State UniversityVerified email at chem.wayne.edu
